Literature DB >> 11095900

Recurrent Bacterial Vaginosis.

.   

Abstract

Bacterial vaginosis (BV) is a common cause of vaginal discharge in women of childbearing age. In some individuals, it recurs frequently after treatment, frustrating both the patient and the physician. Standard BV treatment--metronidazole or clindamycin, administered either intravaginally or orally--is followed by relapse in approximately 30% of cases, within one month. Our inability to prevent relapse reflects our lack of understanding of how BV originates. BV has been associated with infectious morbidity in obstetrics and gynecology. Recent studies have found it to be a risk factor for HIV spread. These findings increase the need for us to be able to control recurrent BV and reduce its prevalence in the general population.

Entities:  

Year:  2000        PMID: 11095900     DOI: 10.1007/s11908-000-0053-5

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  53 in total

Review 1.  Vaginal bacterial phaginosis?

Authors:  A L Blackwell
Journal:  Sex Transm Infect       Date:  1999-10       Impact factor: 3.519

2.  Treatment of bacterial vaginosis.

Authors:  P G Larsson
Journal:  Int J STD AIDS       Date:  1992 Jul-Aug       Impact factor: 1.359

3.  Changes to the cytokine microenvironment in the genital tract mucosa of HIV+ women.

Authors:  A Olaitan; M A Johnson; W M Reid; L W Poulter
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

4.  Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification.

Authors:  E R Boskey; K M Telsch; K J Whaley; T R Moench; R A Cone
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

5.  Sexual behavior risk factors associated with bacterial vaginosis and Chlamydia trachomatis infection.

Authors:  U Nilsson; D Hellberg; M Shoubnikova; S Nilsson; P A Mårdh
Journal:  Sex Transm Dis       Date:  1997-05       Impact factor: 2.830

6.  Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis.

Authors:  C H Livengood; D E Soper; K L Sheehan; D E Fenner; M G Martens; A L Nelson; M Ismail; J M Thorp; M Lappin; B J Long; T Blackwelder; R L Sweet; S Sagov
Journal:  Sex Transm Dis       Date:  1999-03       Impact factor: 2.830

7.  Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation.

Authors:  R P Nugent; M A Krohn; S L Hillier
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

Review 8.  Management of bacterial vaginosis.

Authors: 
Journal:  Drug Ther Bull       Date:  1998-05

9.  Bacterial vaginosis in virginal and sexually active adolescent females: evidence against exclusive sexual transmission.

Authors:  R C Bump; W J Buesching
Journal:  Am J Obstet Gynecol       Date:  1988-04       Impact factor: 8.661

10.  Plasma cell endometritis in women with symptomatic bacterial vaginosis.

Authors:  A P Korn; G Bolan; N Padian; M Ohm-Smith; J Schachter; D V Landers
Journal:  Obstet Gynecol       Date:  1995-03       Impact factor: 7.661

View more
  14 in total

1.  Acceptability of a self-sampling technique to collect vaginal smears for gram stain diagnosis of bacterial vaginosis.

Authors:  Elizabeth R Boskey; Shelly A Atherly-Trim; Patricia J O'Campo; Donna M Strobino; Dawn P Misra; P Misra
Journal:  Womens Health Issues       Date:  2004 Jan-Feb

2.  Antimicrobial Resistance in Vulvovaginitis.

Authors:  Jack D. Sobel
Journal:  Curr Infect Dis Rep       Date:  2001-12       Impact factor: 3.725

3.  Analysis of vaginal acetic acid in patients undergoing treatment for bacterial vaginosis.

Authors:  Amjad N Chaudry; Paul J Travers; Jeffrey Yuenger; Lorraine Colletta; Phillip Evans; Jonathan M Zenilman; Andrew Tummon
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

4.  Evidence for Gardnerella vaginalis uptake and internalization by squamous vaginal epithelial cells: implications for the pathogenesis of bacterial vaginosis.

Authors:  Christy N Marrs; Susan M Knobel; Wen Qin Zhu; Stephanie D Sweet; Ahsen R Chaudhry; Donald J Alcendor
Journal:  Microbes Infect       Date:  2011-12-24       Impact factor: 2.700

Review 5.  Potential uses of probiotics in clinical practice.

Authors:  Gregor Reid; Jana Jass; M Tom Sebulsky; John K McCormick
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

6.  Organisms associated with bacterial vaginosis in Nigerian women as determined by PCR-DGGE and 16S rRNA gene sequence.

Authors:  Kingsley C Anukam; Gregor Reid
Journal:  Afr Health Sci       Date:  2007-06       Impact factor: 0.927

7.  Antibiotic consideration in bacterial vaginosis.

Authors:  Jack D Sobel
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

Review 8.  Managing recurrent bacterial vaginosis.

Authors:  J Wilson
Journal:  Sex Transm Infect       Date:  2004-02       Impact factor: 3.519

9.  Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses.

Authors:  Per-Göran Larsson; Erik Brandsborg; Urban Forsum; Sonal Pendharkar; Kasper Krogh Andersen; Salmir Nasic; Lennart Hammarström; Harold Marcotte
Journal:  BMC Infect Dis       Date:  2011-08-19       Impact factor: 3.090

Review 10.  Bacterial vaginosis, Atopobium vaginae and nifuratel.

Authors:  Franco Polatti
Journal:  Curr Clin Pharmacol       Date:  2012-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.